Unlike some other forms of lymphoma, advanced stage follicular lymphoma is considered incurable. But a new analysis of long-term data on patients treated for the disease years ago with standard regimens of immunotherapy and a chemotherapy combination known as CHOP suggests that many of those patients can now be considered cured. The analysis is just … Read more
A multi-institutional study led by Mayo Clinic and published in Cell Reports Medicine reports that pairing a next-generation immunotherapy with standard hormone therapy before surgery may help overcome a long-standing barrier in early-stage prostate cancer treatment. Immunotherapy has been generally ineffective for prostate cancer because the tumors are considered immunologically “cold,” meaning they do not attract enough immune cells to mount a strong attack. Hormone therapy commonly used for prostate cancer, called androgen … Read more
Among the most promising tools of cancer therapy, engineered immune cells known as chimeric antigen-receptor (CAR) T cells have already transformed the treatment of blood cancers. Yet, despite their promise, CAR-T cells do have their limitations. For one thing, they’ve so far largely failed against solid tumors, which is to say, most types of cancer. … Read more
Patient characteristics at baseline Table of Contents Patient characteristics at baseline Induction therapy with blinatumomab and… The post Bispecific Engagers for Autoimmune Disease | Refractory Cases appeared first on Archynetys. Source link
Immunotherapy – which activates the body’s own immune system to kill cancer cells – has not worked well against a rare and fatal liver cancer, but a new Cornell University study finds an existing FDA-approved drug may allow the immunotherapy to fight the cancer as intended, opening the door to a potential treatment. Fibrolamellar carcinoma … Read more
A new UCLA investigator-initiated study sponsored by the UCLA Health Jonsson Comprehensive Cancer Center has found that adding immunotherapy to standard chemotherapy before surgery is safe and shows promise for some patients with borderline-resectable pancreatic cancer, a disease that has historically been difficult to treat. The findings, published in Nature Communications, show that while the combination did not … Read more
Lung cancer patients who have never smoked make up a significant and growing share of global lung cancer cases, yet remain an understudied group, according to a new review written by UCL (University College London) researchers. In 2020, lung cancer in never-smokers (LCINS) was the fifth most common cause of cancer death worldwide (the most … Read more
A new study sheds light on why some patients with the most aggressive form of ovarian cancer respond better to treatment than others. Tumors positive for a molecule called MHC class II are linked to stronger immune responses and longer survival. These findings from a large study led by the University of Helsinki highlight how … Read more
In recent years, cancer researchers have made major breakthroughs by using the body’s immune system to fight cancer. One of the most promising approaches, known as immune checkpoint blockade, works by releasing molecular “brakes” on T cells. This allows them to better recognize and attack cancer cells. While these therapies can be very effective for … Read more
Cancer cells carry thousands of mutations, but not all mutations are created equal. Some make tumors highly visible to the immune system, while others help cancers hide. In this study, researchers have discovered that across thousands of human cancers, there are five dominant patterns of protein-altering mutations – called amino acid substitution signatures – and … Read more